Access cutting-edge neuroblastoma treatment through this clinical trial at a research site in Hartford. Study-provided care at no cost to qualified participants.
Access neuroblastoma specialists in Hartford at no cost
This study follows strict safety protocols and ethical guidelines
All study-related neuroblastoma treatment provided free
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Sponsor: Giselle Sholler
Check if you qualify for this neuroblastoma clinical trial in Hartford, CT
If you're searching for neuroblastoma treatment options in Hartford, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Hartford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neuroblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.